» Articles » PMID: 22791998

Clinical Utility of Clocortolone Pivalate for the Treatment of Corticosteroid-responsive Skin Disorders: a Systematic Review

Overview
Publisher Dove Medical Press
Specialty Dermatology
Date 2012 Jul 14
PMID 22791998
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Clocortolone pivalate 0.1% cream is a class IV mid-strength topical glucocorticoid. After topical application the glucocorticoid achieves higher concentration in inflamed skin compared with normal skin. Furthermore, pharmacologic studies have shown that there is little systemic absorption of clocortolone pivalate and hence no adrenal suppression. Systematic review was performed to evaluate the efficacy and safety of the glucocorticoid. PubMed, the Cochrane Library, and individual websites of the top 20 dermatology journals were searched using a defined strategy. Following the selection criteria, eight clinical trials were selected, of which five were randomized controlled trials. The trials mainly included patients with atopic dermatitis and eczemas. Quality appraisal of randomized controlled trials was done using the Delphi list, which showed that the trials had weaknesses in several items. The results of the systematic review tend to show that clocortolone pivalate cream is generally effective with early onset of action and has a good safety profile in the treatment of these conditions. Further studies comparing this glucocorticoid with other glucocorticoids and treatments in steroid-responsive dermatoses are desirable.

Citing Articles

Understanding the correlation between structure and dynamics of clocortolone pivalate by solid state NMR measurement.

Dey K, Gayen S, Ghosh M RSC Adv. 2022; 10(8):4310-4321.

PMID: 35495240 PMC: 9049206. DOI: 10.1039/c9ra09866f.


Safety of topical corticosteroids in atopic eczema: an umbrella review.

Axon E, Chalmers J, Santer M, Ridd M, Lawton S, Langan S BMJ Open. 2021; 11(7):e046476.

PMID: 34233978 PMC: 8264889. DOI: 10.1136/bmjopen-2020-046476.

References
1.
Torok H, Maas-Irslinger R, Slayton R . Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis. Cutis. 2003; 72(2):161-6. View

2.
KOLB K, Latza R, Lucker P, RINDT W, Simon B . [Human-pharmacokinetic Studies on Penetration Kinetics of a 6 alpha-Fluoro-9 alpha-chloro-16 alpha-methyl-delta 1,4-pregnadiene-11 beta-dihydroxy-3,20-dione-21-trimethyl-acetic acid (Clocortolone Trimethyl-acetic acid) after e picutaneous...]. Arzneimittelforschung. 1978; 28(9):1648-51. View

3.
. Drugs for allergic disorders. Treat Guidel Med Lett. 2010; 8(90):9-18. View

4.
Barry B, Woodford R . Comparative bio-availability of proprietary topical corticosteroid preparations; vasoconstrictor assays on thirty creams and gels. Br J Dermatol. 1974; 91(3):323-38. DOI: 10.1111/j.1365-2133.1974.tb12903.x. View

5.
Norris D . Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol. 2005; 53(1 Suppl 1):S17-25. DOI: 10.1016/j.jaad.2005.04.027. View